» Articles » PMID: 15153562

Angiotensin II, Via AT1 and AT2 Receptors and NF-kappaB Pathway, Regulates the Inflammatory Response in Unilateral Ureteral Obstruction

Overview
Specialty Nephrology
Date 2004 May 22
PMID 15153562
Citations 87
Authors
Affiliations
Soon will be listed here.
Abstract

Inflammatory cell infiltration plays a key role in the onset and progression of renal injury. The NF-kappaB participates in the inflammatory response, regulating many proinflammatory genes. Angiotensin II (Ang II), via AT(1) and AT(2) receptors, activates NF-kappaB. Although the contribution of Ang II to kidney damage progression is already established, the receptor subtype involved in the inflammatory cell recruitment is not clear. For investigating this issue, the unilateral ureteral obstruction (UUO) model was used in mice, blocking Ang II production/receptors and NF-kappaB pathway. Two days after UUO, obstructed kidneys of wild-type mice presented a marked interstitial inflammatory cell infiltration and increased NF-kappaB activity. Treatment with AT(1) or AT(2) antagonists partially decreased NF-kappaB activation, whereas only the AT(2) blockade diminished monocyte infiltration. Obstructed kidneys of AT(1)-knockout mice showed interstitial monocyte infiltration and NF-kappaB activation; both processes were abolished by an AT(2) antagonist, suggesting AT(2)/NF-kappaB involvement in monocyte recruitment. In wild-type mice, only angiotensin-converting enzyme inhibition or combined therapy with AT(1) plus AT(2) antagonists blocked monocyte infiltration, NF-kappaB activation, and upregulation of NF-kappaB-related proinflammatory genes. Therefore, AT(1) and AT(2) blockade is necessary to arrest completely the inflammatory process. Treatment with two different NF-kappaB inhibitors, pirrolidin-dithiocarbamate and parthenolide, diminished monocyte infiltration and gene overexpression. These data show that Ang II, via AT(1) and AT(2) receptors and NF-kappaB pathway, participates in the regulation of renal monocyte recruitment and may provide a rationale to investigate further the role of AT(2) in human kidney diseases.

Citing Articles

Unlocking the potential of flavonoid-infused drug delivery systems for diabetic wound healing with a mechanistic exploration.

Chowdhury A, Mazumder P Inflammopharmacology. 2024; 32(5):2861-2896.

PMID: 39217278 DOI: 10.1007/s10787-024-01561-5.


Ashwagandha's Multifaceted Effects on Human Health: Impact on Vascular Endothelium, Inflammation, Lipid Metabolism, and Cardiovascular Outcomes-A Review.

Wicinski M, Fajkiel-Madajczyk A, Kurant Z, Liss S, Szyperski P, Szambelan M Nutrients. 2024; 16(15).

PMID: 39125360 PMC: 11314093. DOI: 10.3390/nu16152481.


Altered kidney distribution and loss of ACE2 into the urine in acute kidney injury.

Shirazi M, Cianfarini C, Ismail A, Wysocki J, Wang J, Ye M Am J Physiol Renal Physiol. 2024; 327(3):F412-F425.

PMID: 38961845 PMC: 11460339. DOI: 10.1152/ajprenal.00237.2023.


Renin-angiotensin system inhibitors positively impact on multiple aging regulatory pathways: Could they be used to protect against human aging?.

de Cavanagh E, Inserra F, Ferder L Physiol Rep. 2024; 12(12):e16094.

PMID: 38924381 PMC: 11200104. DOI: 10.14814/phy2.16094.


Current insights into transcriptional role(s) for the nutraceutical in inflammation and aging.

Saha P, Ajgaonkar S, Maniar D, Sahare S, Mehta D, Nair S Front Nutr. 2024; 11:1370951.

PMID: 38765810 PMC: 11099240. DOI: 10.3389/fnut.2024.1370951.